Good ACE, bad ACE do battle in lung injury, SARS

doi:10.1038/nm0805-821

Comment

. 2005 Aug;11(8):821-2.

doi: 10.1038/nm0805-821.

Good ACE, bad ACE do battle in lung injury, SARS

John Nicholls, Malik Peiris

PMID: 16079870
PMCID: PMC7095949
DOI: 10.1038/nm0805-821

Free PMC article

Comment

Good ACE, bad ACE do battle in lung injury, SARS

John Nicholls et al. Nat Med. 2005 Aug.

Free PMC article

. 2005 Aug;11(8):821-2.

doi: 10.1038/nm0805-821.

Authors

John Nicholls, Malik Peiris

PMID: 16079870
PMCID: PMC7095949
DOI: 10.1038/nm0805-821

Favorites

Abstract

Two studies show how the enzyme ACE2 protects against lung injury caused by SARS and other agents. ACE2 seems to counteract the effects of ACE, which are more damaging (pages 875–879).

Figures

Figure 1. Simplified schematic representation of angiotensin-converting enzyme (ACE) regulation of acute lung injury.

ACE converts angiotensin I (AT I) to angiotensin II (AT II) which binds to either angiotensin II receptor 1a (AT1aR), leading to tissue damage and lung edema, or to angiotensin II receptor 2 (AT2R), reducing tissue damage. Angiotensin-converting enzyme 2 (ACE2) in turn converts the potent AT II to a less damaging angiotensin_1–7 (AT_1–7). SARS binds to ACE2, resulting in downregulation through its internalization, and thus reduced inactivation of AT II. Lipopolysaccharide, sepsis and acid treatment also results in ACE2 downregulation. Administration of recombinant ACE2 (rACE2) reduces lung damage by inactivation of AT II and treatment with AT1aR antagonists (ATA) may also have the potential to reduce lung damage. Katie Ris

See this image and copyright information in PMC

Comment on

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. Kuba K, et al. Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10. Nat Med. 2005. PMID: 16007097 Free PMC article.

Cited by 23 articles

Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review.
Lisco G, De Tullio A, Giagulli VA, Guastamacchia E, De Pergola G, Triggiani V. Lisco G, et al. Endocrine. 2020 Aug 10:1-13. doi: 10.1007/s12020-020-02444-9. Online ahead of print. Endocrine. 2020. PMID: 32779091 Free PMC article. Review.
A gendered magnifying glass on COVID-19.
Salvati L, Biagioni B, Vivarelli E, Parronchi P. Salvati L, et al. Clin Mol Allergy. 2020 Aug 4;18:14. doi: 10.1186/s12948-020-00129-2. eCollection 2020. Clin Mol Allergy. 2020. PMID: 32774170 Free PMC article. Review.
Different computed tomography patterns of Coronavirus Disease 2019 (COVID-19) between survivors and non-survivors.
Pan F, Zheng C, Ye T, Li L, Liu D, Li L, Hesketh RL, Yang L. Pan F, et al. Sci Rep. 2020 Jul 9;10(1):11336. doi: 10.1038/s41598-020-68057-4. Sci Rep. 2020. PMID: 32647307 Free PMC article.
Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?
Muraca M, Pessina A, Pozzobon M, Dominici M, Galderisi U, Lazzari L, Parolini O, Lucarelli E, Perilongo G, Baraldi E. Muraca M, et al. J Control Release. 2020 Sep 10;325:135-140. doi: 10.1016/j.jconrel.2020.06.036. Epub 2020 Jul 3. J Control Release. 2020. PMID: 32622963 Free PMC article.
A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic.
Gulati A, Pomeranz C, Qamar Z, Thomas S, Frisch D, George G, Summer R, DeSimone J, Sundaram B. Gulati A, et al. Am J Med Sci. 2020 Jul;360(1):5-34. doi: 10.1016/j.amjms.2020.05.006. Epub 2020 May 11. Am J Med Sci. 2020. PMID: 32620220 Free PMC article. Review.

See all "Cited by" articles

References

1. Abrahams A, Hallows N, French H. Lancet. 1919;196:1–11. doi: 10.1016/S0140-6736(01)22115-1. - DOI
1. Nicholls JM, et al. Lancet. 2003;361:1773–1778. doi: 10.1016/S0140-6736(03)13413-7. - DOI - PMC - PubMed
1. Imai Y, et al. Nature. 2005;436:112–116. doi: 10.1038/nature03712. - DOI - PMC - PubMed
1. Kuba K, et al. Nat. Med. 2005;11:875–879. doi: 10.1038/nm1267. - DOI - PMC - PubMed
1. Li W, et al. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Abrahams A, Hallows N, French H. Lancet. 1919;196:1–11. doi: 10.1016/S0140-6736(01)22115-1. - DOI

[2] Abrahams A, Hallows N, French H. Lancet. 1919;196:1–11. doi: 10.1016/S0140-6736(01)22115-1. - DOI

[3] Nicholls JM, et al. Lancet. 2003;361:1773–1778. doi: 10.1016/S0140-6736(03)13413-7. - DOI - PMC - PubMed

[4] Nicholls JM, et al. Lancet. 2003;361:1773–1778. doi: 10.1016/S0140-6736(03)13413-7. - DOI - PMC - PubMed

[5] Imai Y, et al. Nature. 2005;436:112–116. doi: 10.1038/nature03712. - DOI - PMC - PubMed

[6] Imai Y, et al. Nature. 2005;436:112–116. doi: 10.1038/nature03712. - DOI - PMC - PubMed

[7] Kuba K, et al. Nat. Med. 2005;11:875–879. doi: 10.1038/nm1267. - DOI - PMC - PubMed

[8] Kuba K, et al. Nat. Med. 2005;11:875–879. doi: 10.1038/nm1267. - DOI - PMC - PubMed

[9] Li W, et al. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed

[10] Li W, et al. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Good ACE, bad ACE do battle in lung injury, SARS

Good ACE, bad ACE do battle in lung injury, SARS

Authors

Abstract

Figures

Comment on

Similar articles

Cited by 23 articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous